Hesperetin Therapy for Metabolic Syndrome and Insulin Resistance
Posted Dec 20 2010 7:00pm
Description of Invention: Hesperidin is a flavonoid compound found in citrus fruits. Large epidemiological studies have linked increased consumption of flavonoid-rich foods, such as citrus, with reduced cardiovascular morbidity and mortality. Investigators from the National Center for Complementary and Alternative Medicine have demonstrated that administration of oral hesperidin to patients with metabolic syndrome attenuates biomarkers of inflammation and improves blood vessel relaxation, lipid cholesterol profiles, and insulin sensitivity when compared to controls. Thus, hesperidin and its active aglycone form, hesperetin, may be effective agents for the treatment of diabetes, obesity, metabolic syndrome, dyslipidemias, and their cardiovascular complications including hypertension, atherosclerosis, coronary heart disease, and stroke. This technology discloses methods for using a hesperetin composition to treat metabolic syndrome and insulin resistance.
Applications: Therapeutics for metabolic syndrome and insulin resistance
Development Status: Clinical trial data available
Inventors: Michael J Quon (NCCAM) Ranganath Muniyappa (NCCAM)
Portfolios: Internal Medicine Internal Medicine - Therapeutics
For Licensing Information Please Contact: Tara Kirby Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: tk200h@nih.gov Phone: 301-435-4426 Fax: 301-402-0220
Description of Invention:
Hesperidin is a flavonoid compound found in citrus fruits. Large epidemiological studies have linked increased consumption of flavonoid-rich foods, such as citrus, with reduced cardiovascular morbidity and mortality. Investigators from the National Center for Complementary and Alternative Medicine have demonstrated that administration of oral hesperidin to patients with metabolic syndrome attenuates biomarkers of inflammation and improves blood vessel relaxation, lipid cholesterol profiles, and insulin sensitivity when compared to controls. Thus, hesperidin and its active aglycone form, hesperetin, may be effective agents for the treatment of diabetes, obesity, metabolic syndrome, dyslipidemias, and their cardiovascular complications including hypertension, atherosclerosis, coronary heart disease, and stroke. This technology discloses methods for using a hesperetin composition to treat metabolic syndrome and insulin resistance.
Applications:
Therapeutics for metabolic syndrome and insulin resistance
Development Status:
Clinical trial data available
Inventors:
Michael J Quon (NCCAM)
Ranganath Muniyappa (NCCAM)
Patent Status:
HHS, Reference No. E-148-2010/0
US, Application No. 61/369,229 filed 30 Jul 2010
Relevant Publication:
Licensing Status:
Available for licensing
Portfolios:
Internal Medicine
Internal Medicine - Therapeutics
For Licensing Information Please Contact:
Tara Kirby Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: tk200h@nih.gov
Phone: 301-435-4426
Fax: 301-402-0220
Ref No: 2206
Updated: 12/2010